Conatus Pharmaceuticals Inc (CNAT) Position Lifted by Northern Trust Corp
Northern Trust Corp lifted its position in shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) by 640.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 297,152 shares of the biotechnology company’s stock after purchasing an additional 257,030 shares during the period. Northern Trust Corp owned 1.06% of Conatus Pharmaceuticals worth $1,712,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of Montreal Can bought a new position in shares of Conatus Pharmaceuticals during the second quarter valued at about $109,000. FNY Partners Fund LP increased its holdings in Conatus Pharmaceuticals by 98.0% during the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after buying an additional 9,800 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $115,000. Strs Ohio purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $153,000. Finally, Eagle Global Advisors LLC purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $156,000. 36.99% of the stock is currently owned by institutional investors.
A number of analysts recently issued reports on CNAT shares. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Seaport Global Securities restated a “buy” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Finally, HC Wainwright restated a “buy” rating and set a $17.00 price objective (down previously from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.00.
Shares of Conatus Pharmaceuticals Inc (NASDAQ CNAT) opened at $4.18 on Friday. Conatus Pharmaceuticals Inc has a 1-year low of $1.73 and a 1-year high of $9.40. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.69 and a quick ratio of 2.69.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The company had revenue of $9.57 million for the quarter, compared to analysts’ expectations of $16.06 million. During the same quarter last year, the business posted ($0.31) EPS. equities research analysts expect that Conatus Pharmaceuticals Inc will post -0.65 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Conatus Pharmaceuticals Inc (CNAT) Position Lifted by Northern Trust Corp” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/conatus-pharmaceuticals-inc-cnat-position-lifted-by-northern-trust-corp/1740614.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.